Vertex EVP Biller sells shares in plan trade

Vertex Pharmaceuticals executive Jonathan Biller reported two stock transactions.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Jonathan Biller reported two stock transactions. On February 13, 2026, he disposed of 2,993 shares of common stock at $487.76 per share to cover tax obligations and sold 988 shares in an open-market trade at $499.00 per share. After these transactions, he directly owned 16,838 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on February 24, 2025.

Insider Trade Summary

Net Seller: 988 shares

Net Sell 2 txns

Insider Biller Jonathan

Role EVP and Chief Legal Officer

Sold 988 shs ($493K)

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,993	$487.76	$1.46M
Sale	Common Stock	988	$499.00	$493K

Holdings After Transaction: Common Stock — 16,838 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Jonathan Biller report for VRTX?

Jonathan Biller reported a tax-related share disposition and an open-market sale of Vertex (VRTX) common stock. He disposed of 2,993 shares at $487.76 for tax withholding and sold 988 shares at $499.00 per share on February 13, 2026.

How many VRTX shares does Jonathan Biller own after these transactions?

After the reported transactions, Jonathan Biller directly owns 16,838 shares of Vertex (VRTX) common stock. This reflects both the 2,993-share tax-withholding disposition and the separate 988-share open-market sale completed on February 13, 2026.

Was Jonathan Biller’s VRTX stock sale under a Rule 10b5-1 plan?

Yes, the filing states the transaction was made under a company-approved Rule 10b5-1 trading plan. The plan was entered into on February 24, 2025, providing a pre-arranged framework for selling Vertex (VRTX) shares according to predetermined instructions.

What was the price of Jonathan Biller’s open-market sale of VRTX shares?

Jonathan Biller’s open-market sale of Vertex (VRTX) common stock was executed at $499.00 per share. This sale involved 988 shares on February 13, 2026, separate from the 2,993-share tax-withholding disposition priced at $487.76 per share.

What does the tax-withholding disposition in the VRTX Form 4 mean?

The tax-withholding disposition reflects 2,993 shares of Vertex (VRTX) stock used to satisfy tax liabilities. According to the filing, these shares were valued at $487.76 each and were delivered on February 13, 2026, rather than being sold in an open-market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:26 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Biller Jonathan

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		F		2,993	D	$487.76	17,826	D
Common Stock	02/13/2026		S(1)		988	D	$499	16,838	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.